Jul 16, 2019
Kreher, Chief Medical Officer, Tiburio discusses the
company's lead asset, TBR-760 as a novel treatment option for
patients with non-functioning pituitary adenomas (NFPA), which are
rare neuroendocrine tumors located in the pituitary gland.
She also speaks about the challenges facing patients even after
surgical or radiation treatments for these pituitary tumors.
Download the transcript. Listen to the podcast
#neuroendocrine #pituitaryadenoma #chiefmedicalofficer #raredisease #NFPA